$KZIA News

Kazia Therapeutics Appoints James Levine As CFO, Effective June 1

Kazia Therapeutics Expands Enrollment In Phase 1b Trial For Breast Cancer Treatment Paxalisib

Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst

How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform

Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform

Kazia Therapeutics Announces The In-licensing Of A First-in-class SETDB1-Targeted Epigenetic Drug Development Platform From QIMR Berghofer

Kazia Therapeutics Announces The In-licensing Of A First-in-class SETDB1-Targeted Epigenetic Drug Development Platform From QIMR Berghofer

Kazia Therapeutics Announced Chairman Bryce Carmine Intent To Retire, Effective March 31, 2026

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Announces Preclinical And Translational Data Supporting Development Of NDL2 To Selectively Eliminate Nuclear PD-L1

HC Wainwright & Co. Reiterates Buy on Kazia Therapeutics, Maintains $18 Price Target

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Announces Three Patients With Metastatic Triple-Negative Breast Cancer With Paxalisib-Based Regimens Have Demonstrated Meaningful Clinical Responses In Phase 1b Trial Of Paxalisib In Combination With Pembrolizumab And Chemotherapy

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Nasdaq Compliance

HC Wainwright & Co. Maintains Buy on Kazia Therapeutics, Raises Price Target to $18

Kazia Therapeutics shares are trading higher after the company announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium supporting the activity of paxalisib across both HER2-positive metastatic breast cancer and triple-negative breast cancer.